Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 Drug-Drug Interaction Study
NCT03755778Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelicapavir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) of EDP-938 up to 19 days and Area Under the Curve (AUC) of EDP-938 up to 19 days. Started Nov 2018; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03755778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755778.